Navigation Links
DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
Date:8/6/2012

CUPERTINO, Calif., Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2012. Total revenues were $4.8 million for the three months ended June 30, 2012 as compared to $7.8 million for the three months ended June 30, 2011.  Net loss for the three months ended June 30, 2012 was $4.3 million, compared to a net loss of $5.2 million for the same period in 2011.(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

At June 30, 2012, we had cash and investments of $23.7 million, compared to cash and investments of $26.4 million at March 31, 2012 and $30.8 million at December 31, 2011.  We have no debt obligations, other than normal liabilities associated with running our business."Based on our recent pre-NDA communications with the FDA, we intend to submit a new drug application for POSIDUR in late 2012 or early 2013," stated James E. Brown, D.V.M., President and CEO of DURECT.  "We are also pleased that Pfizer continues to move forward with their efforts to prepare for an FDA interaction later this year with respect to REMOXY and that Zogenix has commenced a Phase I clinical trial for Relday."

Update of Programs:

  • REMOXY® (oxycodone) Extended-Release Capsules CII.  Pfizer has efforts underway to resolve the issues raised in the REMOXY Complete Response Letter and stated in their earnings call on July 31, 2012 that they are analyzing preliminary results from two bioavailability studies and hoping to meet with the FDA in the fourth quarter.  The issues raised in the Complete Response Letter relate primarily to manufacturing.
    REMOXY, an investigational drug, is a unique long acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT's ORADUR
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    5. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
    6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
    7. Luminex Corporation Reports First Quarter 2012 Results
    8. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
    9. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
    10. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
    11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... -- Prostate cancer is the second leading cause of cancer ... caught early - the problem is that too often ... Conditions Education Council (PCEC), – a national organization ... cancer screening –  is sponsoring its 25 th ... Committed to encouraging men to take ...
    (Date:9/22/2014)... , Sept. 22, 2014 CytRx Corporation ... development company specializing in oncology, today announced that study ... clinical trials of aldoxorubicin, a pivotal global Phase 3 ... a global Phase 2b clinical trial in small cell ... for Medical Oncology (ESMO) 2014 Congress being held September ...
    (Date:9/19/2014)... CHAPEL HILL, N.C. , Sept. 19, 2014 ... critical role in forging relationships with key opinion ... the market and competition. Despite the critical nature ... has created many challenges, including altering the landscape ... According to research, the oversight ...
    Breaking Medicine Technology:PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Role of Medical Science Liaisons Shifting in Healthcare Industry 2
    ... the annual,meeting of the Pediatric Academic Societies (PAS) shows ... the start of the typical flu,vaccination season -- healthcare ... children are already in the doctor,s office.,The potential impact ... that less than 20 percent of school-aged children between ...
    ... May 5 N30 Pharma (N30), a,biopharmaceutical company ... that target endogenous s-nitrosothiols,announced today that it has ... with mild to moderate asthma, as well as ... treatment of reactive and,obstructive airway diseases, including Cystic ...
    Cached Medicine Technology:Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors' Visits 2Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors' Visits 3Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors' Visits 4N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201 2
    (Date:9/22/2014)... three-quarters (74%) of parents are aware of online ... (28%) have used those online ratings to choose ... U-M research published today in Pediatrics . ... Children,s Hospital National Poll on Children,s Health, researchers ... physicians influenced their choices in seeking healthcare providers ...
    (Date:9/22/2014)... a drug commonly used to treat diabetes, may raise ... among patients with an underactive thyroid, a new study ... may be associated with heart problems and broken bones, ... study. Among those in the study with an ... levels of thyroid-stimulating hormone per year compared with 322 ...
    (Date:9/22/2014)... “The Race is On!” for the 22nd ... October 12, 2014 as it moves to its new location ... the signature fundraising and awareness event for Susan G. Komen® ... Race for the Cure provides supporters of all ages an ... even sleeping in. , “Moving the Race to Cesar ...
    (Date:9/22/2014)... University of North Carolina at Chapel Hill researchers represents ... people who are experiencing the earliest stages of psychosis. ... development of severe mental disorders such as schizophrenia. Schizophrenia ... about 1 in every 100 people. In severe cases, ... life compromised, and the burden on family members can ...
    (Date:9/22/2014)... Calif. The University of California, Riverside is one ... total of $2.5 million by the National ... zygomycetes ancient lineages of fungi that include plant ... wide variety of organic compounds. , Zygomycetes, used in ... to be among the first terrestrial fungi. Symbiotic associations ...
    Breaking Medicine News(10 mins):Health News:Online ratings influence parents' choices of physicians for their children 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Blood test may help determine who is at risk for psychosis 2Health News:Project launched to study evolutionary history of fungi 2Health News:Project launched to study evolutionary history of fungi 3Health News:Project launched to study evolutionary history of fungi 4
    ... has decided to include Genentech's breast cancer drug, Herceptin ... drug will now be subsidized throughout Australia. ... Australian women would be eligible to start using the ... the government about A$470 million ($356 million) by 2009. ...
    ... Since the start of the one child family policy in ... decreased, and a gross imbalance in the sex ratio// has ... ,The one child family policy has been in force in ... measure. To examine the impact of this policy, researchers analysed ...
    ... the Royal Adelaide Hospital may have found a cheap, ... aged care from becoming vitamin D deficient.// ... in the latest edition of the Medical Journal of ... Cleland, Clinical Professor at the Department of Medicine, University ...
    ... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
    ... new warnings about the risk of psychotic behavior, heart ... on Monday. ,These drugs include Novartis ... Administration spokeswoman, Susan Bro said. ,She ... pressure. They must also include warnings about the risk ...
    ... shot on his family’s farm near Stowmarket Suffolk, has caused ... rabbit flu.// ,John Freeman, 29, had become infected ... a rabbit on his farm. His mother explained that he ... after three days. ,It was revealed by the ...
    Cached Medicine News:Health News:Lower Birth Rate and Fewer Girls under China’s one Child Polic 2Health News:Improving Vitamin D Levels in Aged Care Residents 2Health News:New Alerts Needed for ADHD drugs 2
    The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
    ... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...
    ... table MARS Enduro is the ideal ... are required before, during or directly ... motorised longitudinal adjustment and the filigreed ... conditions in examination, induction and operating ...
    ... Top Rotation provides uncommon bi-directional flexibility, ... Hercules 6700B eliminates any conflicts between ... while providing ample leg room for ... procedures. Removable back and leg sections ...
    Medicine Products: